Much confusion has been generated among medical professionals and men diagnosed with low-risk prostate cancer by a recent radical rethink on treatment guidelines published by the US National Comprehensive Cancer Network. The NCCN is a well-respected body that for years has supported the generally accepted approach that the best treatment for men diagnosed with low-risk prostate cancer is to do nothing — or, rather, to monitor the progress of the disease through “active surveillance”. Now